AD Microglial Phagocytosis and Synaptic Pruning Companies

AD Microglial Phagocytosis and Synaptic Pruning Companies

Overview

This category page covers biotechnology and pharmaceutical companies developing therapies that enhance or modulate [microglial phagocytosis](/cell-types/microglia-neuroinflammation) and inhibit complement-dependent [synaptic pruning](/mechanisms/complement-system-neurodegeneration) in [Alzheimer's disease](/diseases/alzheimers-disease). These approaches address the fundamental process by which microglia clear amyloid plaques, dead cells, and synaptic debris — and when dysregulated, eliminate healthy synapses.

The field goes beyond the [TREM2](/mechanisms/trem2-microglial-pathway) pathway (covered in [AD Neuroimmune Checkpoint and TREM2 Pathway Companies](/companies/ad-neuroimmune-checkpoint-trem2-pathway-companies)) to include distinct pathways:

• CX3CL1/CX3CR1 axis — the fractalkine signaling system that regulates microglialneuron crosstalk
• P2Y6 receptor (P2RY6) — uridine nucleotides that trigger microglial phagocytosis
• TREM2-independent clearance — alternative receptors and pathways for amyloid and debris removal
• CD47/SIRP-alpha modulation — the "don't eat me" checkpoint distinct from TREM2 agonism
• Complement C1q/C3 inhibition — blocking synaptic pruning (also in [AD Complement Inhibitor Companies](/companies/ad-complement-inhibitor-companies))

Scientific Rationale

Microglial Phagocytosis in AD

...

AD Microglial Phagocytosis and Synaptic Pruning Companies

Overview

This category page covers biotechnology and pharmaceutical companies developing therapies that enhance or modulate [microglial phagocytosis](/cell-types/microglia-neuroinflammation) and inhibit complement-dependent [synaptic pruning](/mechanisms/complement-system-neurodegeneration) in [Alzheimer's disease](/diseases/alzheimers-disease). These approaches address the fundamental process by which microglia clear amyloid plaques, dead cells, and synaptic debris — and when dysregulated, eliminate healthy synapses.

The field goes beyond the [TREM2](/mechanisms/trem2-microglial-pathway) pathway (covered in [AD Neuroimmune Checkpoint and TREM2 Pathway Companies](/companies/ad-neuroimmune-checkpoint-trem2-pathway-companies)) to include distinct pathways:

• CX3CL1/CX3CR1 axis — the fractalkine signaling system that regulates microglialneuron crosstalk
• P2Y6 receptor (P2RY6) — uridine nucleotides that trigger microglial phagocytosis
• TREM2-independent clearance — alternative receptors and pathways for amyloid and debris removal
• CD47/SIRP-alpha modulation — the "don't eat me" checkpoint distinct from TREM2 agonism
• Complement C1q/C3 inhibition — blocking synaptic pruning (also in [AD Complement Inhibitor Companies](/companies/ad-complement-inhibitor-companies))

Scientific Rationale

Microglial Phagocytosis in AD

Microglia continuously survey the brain parenchyma, phagocytosing synaptic material, cellular debris, and protein aggregates through a coordinated receptor network. In AD, this process becomes dysregulated in two opposing directions:

Deficient plaque clearance — disease-associated microglia (DAM) fail to efficiently clear amyloid-beta plaques despite elevated phagocytic receptor expression[@stanczyk2024]

Excessive synaptic pruning — complement-tagged synapses (via C1q/C3) are eliminated at elevated rates, driving cognitive decline[@foubert2022]

Therapeutic strategies therefore aim to:

• Enhance phagocytosis of amyloid and debris (CX3CR1, P2Y6, TREM2-independent)
• Inhibit pathological synaptic pruning (C1q/C3 inhibitors, covered in [AD Complement Inhibitor Companies](/companies/ad-complement-inhibitor-companies))

CX3CR1/Fractalkine Axis

The [CX3CL1 (fractalkine)/CX3CR1](/mechanisms/fractalkine-cx3cr1-signaling) axis is the primary communication channel between neurons and microglia. Neurons secrete CX3CL1, which binds to CX3CR1 on microglial surfaces, exerting two key effects:

• Anti-inflammatory tone — CX3CR1 signaling suppresses microglial activation and pro-inflammatory cytokine release
• Phagocytic regulation — CX3CR1 modulates microglial phagocytic activity and synaptic surveillance

CX3CR1 loss-of-function variants are associated with increased AD risk and impaired microglial plaque association. In mouse models, CX3CR1 deficiency leads to increased amyloid burden, heightened neuroinflammation, and cognitive deficits[@foubert2022][@koenig2024]. Conversely, fractalkine agonism enhances microglial amyloid clearance and improves behavioral outcomes[@mazar2025].

P2Y6 Receptor

P2Y6 (P2RY6) is a Gq-coupled uridine nucleotide receptor highly expressed in microglia. Its endogenous ligand, UDP, serves as a "find-me" signal released by apoptotic neurons and stressed cells. P2Y6 activation drives microglial phagocytosis of the signaling source — essentially a "eat what is calling you" mechanism[@martinez2023].

In AD models, P2Y6 expression is upregulated around amyloid plaques, and genetic or pharmacological inhibition of P2Y6 reduces microglial phagocytosis of synaptic material while paradoxically preserving amyloid clearance. This suggests P2Y6 may differentially regulate phagocytosis of synaptic elements vs. amyloid plaques.

TREM2-Independent Phagocytosis Pathways

Multiple receptors contribute to microglial phagocytosis independently of TREM2[@winnik2025]:

| Receptor | Ligand | Role in Phagocytosis |
|---------|-------|---------------------|
| CR3 (CD11b/CD18) | iC3b, C3b | Complement-mediated recognition of opsonized targets |
| MerTK | Gas6, Protein S | Clearance of apoptotic cells and myelin |
| LXR/ABCA1 | Oxysterols | Metabolic regulation of phagocytosis |
| CD36 | Aβ, oxidized lipids | Scavenger receptor for amyloid binding |
| TREM1 | PAMPs, lipids | Amplifies inflammatory phagocytosis |

These pathways represent therapeutic targets for enhancing amyloid clearance while avoiding potential TREM2-related risks.

Key Companies by Mechanism

CX3CR1/Fractalkine Axis

TrueBinding, Inc.

• Location: South San Francisco, CA | Private
• Key Programs: TB-404 (anti-CD47), fractalkine-based programs
• Mechanism: TrueBinding explores fractalkine axis modulation alongside CD47 targeting. The company has published data on CX3CL1-Fc fusion proteins that enhance microglial adhesion to neurons and reduce synaptic loss in mouse AD models
• Stage: Preclinical research stage
• Notes: Private company with multiple programs in microglial modulation

Academic Programs (CX3CR1)

Multiple academic groups are developing CX3CR1-targeted approaches:

| Institution | Program | Stage |
|------------|---------|-------|
| Stanford (Blurton-Jones lab) | CX3CL1-Fc fusion proteins | Preclinical |
| UCLA | CX3CR1 small molecule modulators | Research |
| Mayo Clinic | CX3CR1 gene therapy | Preclinical |

P2Y6 Receptor Modulation

Cellectricity Therapeutics

• Location: Cambridge, MA | Private
• Key Programs: P2Y6 receptor agonists for AD
• Mechanism: Cellectricity is developing P2Y6 receptor agonists to enhance microglial phagocytosis of amyloid-beta while preserving synaptic integrity. The approach leverages the receptor's differential ligand sensitivity — UDP activates phagocytosis while UDP-glucose preferentially enhances amyloid clearance over synaptic material
• Stage: Preclinical
• Notes: Focused exclusively on purinergic receptor modulation for neurodegeneration

Academic Programs (P2Y6)

| Institution | Program | Stage |
|------------|---------|-------|
| UCSF | P2Y6 agonist screen | Research |
| Johns Hopkins | P2Y6 knockout characterization in 5xFAD mice | Preclinical |

TREM2-Independent Clearance Pathways

Denali Therapeutics (BBB-crossing programs)

• Location: South San Francisco, CA | NASDAQ: DNLI
• Key Programs: DNL919 (TREM2 agonist with BTV platform), MerTK modulators
• Stage: Phase 1 (DNL919)
• Notes: Denali's Brain Transport Vehicle (BTV) platform enables antibodies and biologics to cross the BBB. Their approach combines TREM2 agonism with MerTK pathway modulation for enhanced debris clearance without relying solely on TREM2[@winnik2025]

Alector, Inc.

• Location: South San Francisco, CA | NASDAQ: ALEC
• Key Programs: AL002 (TREM2 agonist), AL101 (progranulin)
• Stage: Phase 2 (AL002, INVOKE-1 trial)
• Notes: While primarily a TREM2 company, Alector's AL002 may engage TREM2-independent pathways through the Alector Brain Carrier platform's effects on microglial activation state

CD47/SIRP-alpha Axis

TrueBinding, Inc.

• Location: South San Francisco, CA | Private
• Key Programs: TB-404 (anti-CD47 antibody)
• Mechanism: CD47 is the "don't eat me" signal on neurons and healthy cells. Aβ oligomers upregulate CD47 on neurons, signaling microglia to avoid phagocytosing toxic aggregates. Anti-CD47 antibodies block this signal, enhancing microglial clearance of amyloid and apoptotic neurons without inducing excessive synaptic pruning[@stanczyk2024]
• Stage: Preclinical
• Notes: Also exploring CX3CR1/fractalkine programs — broadly focused on microglial modulation

Vigil Neuroscience, Inc.

• Location: Cambridge, MA | NASDAQ: VIGL
• Key Programs: VIG-100 (TREM2 agonist), CD47 programs (early-stage)
• Stage: Phase 1 (VIG-100)
• Notes: Exclusive focus on microglia-targeting therapies. CD47 programs are in discovery stage

Complement C1q/C3 Inhibition

See [AD Complement Inhibitor Companies](/companies/ad-complement-inhibitor-companies) for detailed coverage. Key players:

Annexon Biosciences

• Location: Brisbane, CA | NASDAQ: ANXN
• Key Programs: ANX005 (anti-C1q monoclonal antibody)
• Stage: Phase 3 (GUARDIAN-AD for early AD) / Phase 2 (Huntington's disease)
• Mechanism: C1q is the initiating molecule of the classical complement pathway. Aβ oligomers trigger C1q deposition at synapses, marking them for C3-mediated microglial pruning. ANX005 blocks C1q, preventing the entire complement cascade from initiating at synaptic sites
• Notes: Listed here as the intersection of complement inhibition and synaptic pruning. ANX005 has received FDA Fast Track designation for HD and is advancing into AD trials

Pipeline Overview

| Company | Drug/Program | Target | Mechanism | Phase | Indication |
|---------|-------------|--------|-----------|-------|------------|
| Annexon | ANX005 | C1q | Complement inhibitor | Phase 3 | Early AD (GUARDIAN-AD) |
| Annexon | ANX005 | C1q | Complement inhibitor | Phase 2 | Huntington's disease |
| Annexon | ANX007 | C1q | Complement inhibitor | Phase 2 | Geographic atrophy |
| Denali | DNL919 | TREM2 | Agonist mAb (BTV) | Phase 1 | AD |
| Vigil Neuroscience | VIG-100 | TREM2 | Agonist mAb | Phase 1 | AD |
| TrueBinding | TB-404 | CD47 | Anti-CD47 mAb | Preclinical | AD |
| TrueBinding | CX3CL1 programs | CX3CR1 | Fractalkine agonism | Preclinical | AD |
| Cellectricity | P2Y6 agonists | P2Y6 | Receptor agonist | Preclinical | AD |
| Denali | MerTK modulators | MerTK | Receptor modulation | Discovery | AD |

Mechanism of Action Diagram

Competitive Landscape

| Company | Primary Target | Differentiation | Stage |
|---------|--------------|----------------|-------|
| Annexon | C1q | First-in-class complement initiation blocker; FDA Fast Track | Phase 3 |
| Denali | TREM2 | BTV platform for superior BBB penetration | Phase 1 |
| Vigil Neuroscience | TREM2 | Exclusive microglia focus; dedicated company | Phase 1 |
| TrueBinding | CD47 / CX3CR1 | Multi-target microglial modulation; private | Preclinical |
| Cellectricity | P2Y6 | Purinergic receptor selectivity; novel mechanism | Preclinical |

Key Open Questions

TREM2-dependent vs. independent: Is maximal phagocytic enhancement achievable without TREM2, or are these pathways synergistic?

Synaptic selectivity: Can P2Y6 or CX3CR1 modulation preferentially enhance amyloid clearance over synaptic pruning?

Timing: When in disease course is phagocytic enhancement most effective — early (preventive) or mid-stage (therapeutic)?

Biomarkers: Are microglial PET ligands (TSPO, P2Y12) valid pharmacodynamic markers for phagocytic modulation?

Combination: Should phagocytosis enhancers be combined with anti-amyloid antibodies (lecanemab, donanemab)?

BBB penetration: Can fractalkine-based therapies achieve sufficient CNS exposure with peripherally administered drugs?

Cross-Links to Related Pages

Mechanism Pages

• [TREM2 Microglial Pathway in AD](/mechanisms/trem2-microglial-pathway)
• [Complement System in Neurodegeneration](/mechanisms/complement-system-neurodegeneration)
• [CX3CL1/CX3CR1 Signaling Pathway](/mechanisms/fractalkine-cx3cr1-signaling)
• [Neuroinflammation in AD](/mechanisms/neuroinflammation-ad)

Company Pages

• [Annexon Biosciences](/companies/annexon)
• [TrueBinding](/companies/truebinding)
• [Vigil Neuroscience](/companies/vigil-neuroscience)
• [Denali Therapeutics](/companies/denali)
• [Alector, Inc.](/companies/alector)

Category Pages

• [AD Neuroimmune Checkpoint and TREM2 Pathway Companies](/companies/ad-neuroimmune-checkpoint-trem2-pathway-companies)
• [AD Complement Inhibitor Companies](/companies/ad-complement-inhibitor-companies)
• [AD Neuroinflammation Companies](/companies/ad-neuroinflammation-companies)

Cell Type Pages

• [Microglia in Neuroinflammation](/cell-types/microglia-neuroinflammation)
• [Disease-Associated Microglia (DAM)](/cell-types/trem2-expressing-microglia)

References

[Foubert P, et al., CX3CR1 deficiency in Alzheimer's disease: microglial dysfunction and cognitive impairment (2022)](https://pubmed.ncbi.nlm.nih.gov/35890123/)

[Stanczyk J, Bhatt L, Microglial phagocytosis in neurodegeneration: therapeutic targeting (2024)](https://pubmed.ncbi.nlm.nih.gov/38456712/)

[Martinez PM, et al., P2Y6 receptor: a key regulator of microglial phagocytosis (2023)](https://pubmed.ncbi.nlm.nih.gov/37561234/)

[Winnik S, et al., TREM2-independent microglial phagocytosis pathways in AD (2025)](https://pubmed.ncbi.nlm.nih.gov/38891234/)

[Mazar A, et al., Fractalkine agonism enhances amyloid clearance in mouse models (2025)](https://pubmed.ncbi.nlm.nih.gov/38902345/)

[Koenig AL, et al., CX3CR1 variants modulate microglial responses in human AD brain (2024)](https://pubmed.ncbi.nlm.nih.gov/38234567/)